Ampliphi Biosciences Stock Price, News & Analysis (NYSEAMERICAN:APHB)

$1.22 0.00 (0.00 %)
(As of 02/18/2018 04:00 PM ET)
Previous Close$1.22
Today's Range$1.20 - $1.25
52-Week Range$0.67 - $5.80
Volume208,137 shs
Average Volume1.03 million shs
Market Capitalization$16.26 million
P/E Ratio-0.12
Dividend YieldN/A
Beta3.2

About Ampliphi Biosciences (NYSEAMERICAN:APHB)

Ampliphi Biosciences logoAmpliPhi Biosciences Corporation is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products. The Company is engaged in developing these phage product candidates using a discovery and development platform, which is designed for identification, characterization and manufacturing of multiple phage therapies. Each product candidate combines several chosen phages, which target a specific disease-causing bacterial pathogen, such as staphylococcus aureus (S. aureus), Pseudomonas aeruginosa (P. aeruginosa) and clostridium difficile (C. difficile). Its product candidates include AB-SA01, AB-PA01 and AB-CD01.

Receive APHB News and Ratings via Email

Sign-up to receive the latest news and ratings for APHB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorBiotechnology & Medical Research - NEC
SymbolNYSEAMERICAN:APHB
CUSIPN/A
Phone+1-804-8272524

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-0.119257086999022
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($10.23)
Net IncomeN/A
Net Margins-2,050.00%
Return on Equity-31.85%
Return on Assets-21.63%

Miscellaneous

EmployeesN/A
Outstanding Shares9,500,000

Ampliphi Biosciences (NYSEAMERICAN:APHB) Frequently Asked Questions

What is Ampliphi Biosciences' stock symbol?

Ampliphi Biosciences trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "APHB."

How were Ampliphi Biosciences' earnings last quarter?

Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) released its quarterly earnings results on Monday, August, 15th. The biotechnology company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.66) by $0.12. Ampliphi Biosciences had a negative net margin of 2,050.00% and a negative return on equity of 31.85%. View Ampliphi Biosciences' Earnings History.

When will Ampliphi Biosciences make its next earnings announcement?

Ampliphi Biosciences is scheduled to release their next quarterly earnings announcement on Monday, March, 26th 2018. View Earnings Estimates for Ampliphi Biosciences.

Where is Ampliphi Biosciences' stock going? Where will Ampliphi Biosciences' stock price be in 2018?

1 analysts have issued twelve-month price targets for Ampliphi Biosciences' stock. Their forecasts range from $6.00 to $6.00. On average, they expect Ampliphi Biosciences' share price to reach $6.00 in the next year. View Analyst Ratings for Ampliphi Biosciences.

Are investors shorting Ampliphi Biosciences?

Ampliphi Biosciences saw a decline in short interest during the month of January. As of January 31st, there was short interest totalling 945,998 shares, a decline of 18.7% from the January 12th total of 1,163,534 shares. Based on an average daily trading volume, of 801,494 shares, the days-to-cover ratio is presently 1.2 days. Approximately 10.1% of the company's shares are sold short.

Who are some of Ampliphi Biosciences' key competitors?

Who are Ampliphi Biosciences' key executives?

Ampliphi Biosciences' management team includes the folowing people:

  • Jeremy Laurence Curnock-Cook, Chairman of the Board (Age 66)
  • Paul C. Grint M.D., Chief Executive Officer, Director (Age 59)
  • Steven Robert Martin, Chief Financial Officer (Age 54)
  • Igor P. Bilinsky Ph.D., Chief Operating Officer, Senior Vice President (Age 43)
  • Louis C. Drapeau CPA, Director (Age 72)
  • Wendy S. Johnson, Director (Age 64)
  • Michael S. Perry Ph.D., Director (Age 57)
  • Vijay B. Samant, Director (Age 63)

Who owns Ampliphi Biosciences stock?

Ampliphi Biosciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include EMPERY ASSET MANAGEMENT, LP (7.50%). Company insiders that own Ampliphi Biosciences stock include Jeremy Curnock Cook and Randal J Kirk. View Institutional Ownership Trends for Ampliphi Biosciences.

How do I buy Ampliphi Biosciences stock?

Shares of Ampliphi Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ampliphi Biosciences' stock price today?

One share of Ampliphi Biosciences stock can currently be purchased for approximately $1.22.

How big of a company is Ampliphi Biosciences?

Ampliphi Biosciences has a market capitalization of $16.26 million.

How can I contact Ampliphi Biosciences?

Ampliphi Biosciences' mailing address is 3579 Valley Centre Drive, SAN DIEGO, CA 92130, United States. The biotechnology company can be reached via phone at +1-804-8272524.


MarketBeat Community Rating for Ampliphi Biosciences (APHB)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  94 (Vote Outperform)
Underperform Votes:  56 (Vote Underperform)
Total Votes:  150
MarketBeat's community ratings are surveys of what our community members think about Ampliphi Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ampliphi Biosciences (NYSEAMERICAN:APHB) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.00$6.00$7.50$10.00
Price Target Upside: 450.46% upside450.46% upside772.09% upside1,826.41% upside

Ampliphi Biosciences (NYSEAMERICAN:APHB) Consensus Price Target History

Price Target History for Ampliphi Biosciences (NYSEAMERICAN:APHB)

Ampliphi Biosciences (NYSEAMERICAN:APHB) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
1/17/2018HC WainwrightBoost Price TargetBuy -> Buy$5.00 -> $6.00View Rating Details
1/24/2017Roth CapitalReiterated RatingBuyView Rating Details
3/8/2016Griffin SecuritiesReiterated RatingBuyView Rating Details
(Data available from 2/18/2016 forward)

Earnings

Ampliphi Biosciences (NYSEAMERICAN:APHB) Earnings History and Estimates Chart

Earnings by Quarter for Ampliphi Biosciences (NYSEAMERICAN:APHB)

Ampliphi Biosciences (NYSEAMERICAN APHB) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/26/2018($0.37)N/AView Earnings Details
11/14/2017Q3 2017($0.46)($0.09)ViewN/AView Earnings Details
8/14/2017Q2 2017($0.80)($0.78)$0.03 millionViewN/AView Earnings Details
5/15/2017Q1 2017($8.20)($1.94)ViewN/AView Earnings Details
3/27/2017Q4 2016($3.30)($3.20)ViewN/AView Earnings Details
11/10/2016Q3 2016($3.80)($3.20)ViewN/AView Earnings Details
8/15/2016Q216($0.66)($0.78)ViewListenView Earnings Details
5/12/2016Q116($0.68)($0.82)ViewN/AView Earnings Details
3/30/2016Q415($0.40)($0.43)ViewN/AView Earnings Details
11/16/2015Q3 2015($2.00)($3.00)ViewN/AView Earnings Details
8/13/2015Q2 2015($7.50)($5.70)ViewN/AView Earnings Details
5/15/2015Q1 2015($5.00)($5.00)ViewN/AView Earnings Details
4/15/2015Q4 2014($5.00)($5.00)ViewN/AView Earnings Details
11/18/2014($0.02)$0.06ViewN/AView Earnings Details
9/24/2014($0.02)($0.01)ViewN/AView Earnings Details
9/12/2014Q2 2014($10.00)($5.00)ViewN/AView Earnings Details
5/20/2014Q1 2014($10.00)($30.00)ViewN/AView Earnings Details
6/1/2010Q4 2009$42.50ViewN/AView Earnings Details
11/16/2009Q3 2009$16.00ViewN/AView Earnings Details
8/12/2009Q2 2009$345.50ViewN/AView Earnings Details
5/7/2009Q1 2009($35.50)ViewN/AView Earnings Details
3/31/2009Q4 2008($64.00)ViewN/AView Earnings Details
8/6/2008Q2 2008($85.00)($95.50)ViewN/AView Earnings Details
5/7/2008Q1 2008($150.00)($81.00)ViewN/AView Earnings Details
3/25/2008Q4 2007($94.00)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Ampliphi Biosciences (NYSEAMERICAN:APHB) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Ampliphi Biosciences (NYSEAMERICAN:APHB)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Ampliphi Biosciences (NYSEAMERICAN APHB) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Ampliphi Biosciences (NYSEAMERICAN:APHB)

Ampliphi Biosciences (NYSEAMERICAN APHB) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/29/2016Randal J KirkMajor ShareholderSell177,020$0.48$84,969.60View SEC Filing  
4/8/2016Jeremy Curnock CookDirectorBuy239,753$2.36$565,817.08View SEC Filing  
10/6/2015Louis DrapeauDirectorBuy10,000$4.39$43,900.0010,000View SEC Filing  
10/5/2015Michael Scott SalkaCEOBuy4,200$4.75$19,950.004,200View SEC Filing  
10/5/2015Wendy S JohnsonInsiderBuy1,000$4.43$4,430.001,000View SEC Filing  
3/16/2015Randal J KirkMajor ShareholderBuy13,939,392$0.17$2,369,696.64View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Ampliphi Biosciences (NYSEAMERICAN APHB) News Headlines

Source:
DateHeadline
Ampliphi Biosciences Corp (APHB) Short Interest Down 18.7% in JanuaryAmpliphi Biosciences Corp (APHB) Short Interest Down 18.7% in January
www.americanbankingnews.com - February 9 at 6:58 PM
Ampliphi Biosciences Corp (APHB) Sees Large Increase in Short InterestAmpliphi Biosciences Corp (APHB) Sees Large Increase in Short Interest
www.americanbankingnews.com - January 24 at 6:10 PM
Best High Growth AMEX Stocks This WeekBest High Growth AMEX Stocks This Week
finance.yahoo.com - January 21 at 5:16 PM
ALRN To Report Data In 1H18, DFFN On Watch, D-Day Awaits ARDMALRN To Report Data In 1H18, DFFN On Watch, D-Day Awaits ARDM
www.nasdaq.com - January 11 at 9:08 AM
AmpliPhi Biosciences (APHB) Prices 4M Share Common Offering at $1/ShAmpliPhi Biosciences (APHB) Prices 4M Share Common Offering at $1/Sh
www.streetinsider.com - January 11 at 9:08 AM
Ampliphi Biosciences Corp (APHB) Sees Significant Decrease in Short InterestAmpliphi Biosciences Corp (APHB) Sees Significant Decrease in Short Interest
www.americanbankingnews.com - January 11 at 2:36 AM
Mid-Morning Market Update: Markets Open Lower; Lennar Earnings Miss ExpectationsMid-Morning Market Update: Markets Open Lower; Lennar Earnings Miss Expectations
www.benzinga.com - January 10 at 11:30 AM
LPCN Awaits FDA Panel Vote Today, APHB Slumps, BGNE Crosses $100 AgainLPCN Awaits FDA Panel Vote Today, APHB Slumps, BGNE Crosses $100 Again
www.nasdaq.com - January 10 at 8:58 AM
AmpliPhi Biosciences Announces Pricing of $4.0 Million Public Offering of Common StockAmpliPhi Biosciences Announces Pricing of $4.0 Million Public Offering of Common Stock
finance.yahoo.com - January 10 at 8:58 AM
AmpliPhi Biosciences Announces Proposed Public Offering of Common StockAmpliPhi Biosciences Announces Proposed Public Offering of Common Stock
finance.yahoo.com - January 9 at 6:06 PM
APHB: Reports Positive Interim Results for Expanded Access ProgramAPHB: Reports Positive Interim Results for Expanded Access Program
finance.yahoo.com - January 5 at 11:43 AM
APHB Is A Good Shot, ASND Keeps Inching Along, SKLN Soars ... - NasdaqAPHB Is A Good Shot, ASND Keeps Inching Along, SKLN Soars ... - Nasdaq
www.nasdaq.com - January 4 at 8:52 AM
AmpliPhi Biosciences (APHB) Reports Interim Results for Single-Patient Expanded Access Program Utilizing AB-SA01 and AB-PA01AmpliPhi Biosciences (APHB) Reports Interim Results for Single-Patient Expanded Access Program Utilizing AB-SA01 and AB-PA01
www.streetinsider.com - January 3 at 4:18 PM
AmpliPhi Biosciences Announces Positive Interim Results for Single-Patient Expanded Access Program Utilizing AB-SA01 and AB-PA01AmpliPhi Biosciences Announces Positive Interim Results for Single-Patient Expanded Access Program Utilizing AB-SA01 and AB-PA01
finance.yahoo.com - January 3 at 4:13 PM
AmpliPhi Biosciences to Present at Biotech Showcase 2018AmpliPhi Biosciences to Present at Biotech Showcase 2018
finance.yahoo.com - January 2 at 4:51 PM
Ampliphi Biosciences Corp (APHB) Short Interest Down 11.5% in DecemberAmpliphi Biosciences Corp (APHB) Short Interest Down 11.5% in December
www.americanbankingnews.com - December 28 at 1:26 AM
Best NasdaqGM Growth StocksBest NasdaqGM Growth Stocks
finance.yahoo.com - December 20 at 11:27 AM
Health Care Sector Update for 12/15/2017: APHB,SGRY,GLYC,ECYT,TTPH,CASC - NasdaqHealth Care Sector Update for 12/15/2017: APHB,SGRY,GLYC,ECYT,TTPH,CASC - Nasdaq
www.nasdaq.com - December 16 at 8:54 AM
After-Hours Stock Movers 12/14: (DDR) (HES) (DISCA) Higher; (VSTM) (APHB ...After-Hours Stock Movers 12/14: (DDR) (HES) (DISCA) Higher; (VSTM) (APHB ...
www.streetinsider.com - December 15 at 9:09 AM
After-Hours Stock Movers 12/14: (DDR) (HES) (DISCA) Higher; (VSTM) (APHB) (ORCL) Lower (more...) - StreetInsider.comAfter-Hours Stock Movers 12/14: (DDR) (HES) (DISCA) Higher; (VSTM) (APHB) (ORCL) Lower (more...) - StreetInsider.com
www.streetinsider.com - December 14 at 6:26 PM
AmpliPhi Biosciences (APHB) Announces Corporate and Strategic Update - StreetInsider.comAmpliPhi Biosciences (APHB) Announces Corporate and Strategic Update - StreetInsider.com
www.streetinsider.com - December 14 at 4:42 PM
AmpliPhi Biosciences Provides Corporate and Strategic UpdateAmpliPhi Biosciences Provides Corporate and Strategic Update
finance.yahoo.com - December 14 at 4:41 PM
Ampliphi Biosciences Corp (APHB) Short Interest UpdateAmpliphi Biosciences Corp (APHB) Short Interest Update
www.americanbankingnews.com - December 12 at 2:26 AM
AmpliPhi Biosciences Corp. :APHB-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017AmpliPhi Biosciences Corp. :APHB-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
finance.yahoo.com - November 29 at 8:50 AM
Ampliphi Biosciences Corp (APHB) Short Interest Down 14.8% in NovemberAmpliphi Biosciences Corp (APHB) Short Interest Down 14.8% in November
www.americanbankingnews.com - November 27 at 9:56 PM
APHB: Six Patients Treated So Far With AB-SA01 and AB-PA01 Under Expanded Access ProgramsAPHB: Six Patients Treated So Far With AB-SA01 and AB-PA01 Under Expanded Access Programs
finance.yahoo.com - November 17 at 3:41 PM
Ampliphi Biosciences Corps (APHB) Buy Rating Reaffirmed at HC WainwrightAmpliphi Biosciences Corp's (APHB) Buy Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - November 15 at 9:56 AM
AmpliPhi Biosciences (APHB) CEO Paul Grint on Q3 2017 Results ... - Seeking AlphaAmpliPhi Biosciences' (APHB) CEO Paul Grint on Q3 2017 Results ... - Seeking Alpha
seekingalpha.com - November 15 at 2:32 AM

SEC Filings

Ampliphi Biosciences (NYSEAMERICAN:APHB) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Ampliphi Biosciences (NYSEAMERICAN:APHB) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Ampliphi Biosciences (NYSEAMERICAN APHB) Stock Chart for Sunday, February, 18, 2018

Loading chart…

This page was last updated on 2/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.